BR112016027936A2 - peptídeo derivado de socs1 para o seu uso em complicações crônicas da diabetes - Google Patents

peptídeo derivado de socs1 para o seu uso em complicações crônicas da diabetes

Info

Publication number
BR112016027936A2
BR112016027936A2 BR112016027936A BR112016027936A BR112016027936A2 BR 112016027936 A2 BR112016027936 A2 BR 112016027936A2 BR 112016027936 A BR112016027936 A BR 112016027936A BR 112016027936 A BR112016027936 A BR 112016027936A BR 112016027936 A2 BR112016027936 A2 BR 112016027936A2
Authority
BR
Brazil
Prior art keywords
socs1
derived peptide
diabetes complications
chronic diabetes
complications
Prior art date
Application number
BR112016027936A
Other languages
English (en)
Inventor
GÓMEZ GUERRERO Carmen
HERNÁNDEZ PASCUAL Cristina
Egido De Los Ríos Jesús
SIMÓ CANONGE Rafael
Original Assignee
Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Hospital Univ Vall Dhebron Institut De Recerca, Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz, Univ Madrid Autonoma filed Critical Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Publication of BR112016027936A2 publication Critical patent/BR112016027936A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

peptídeo derivado de socs1 para seu uso em complicações crônicas da diabetes, especialmente complicações oculares, renais, nervosas e vasculares, assim como composições que o contêm polinucleotídeos isolados que o codificam. a presente invenção também se refere ao peptídeo derivado de socs1 para o seu uso tópico no tratamento e/ou prevenção de doenças neurodegenerativas da retina, em particular nas primeiras etapas d retinopatia diabética e outras doenças da retina nas quais a neurodegeneração desempenha um papel essencial.
BR112016027936A 2014-05-28 2015-05-27 peptídeo derivado de socs1 para o seu uso em complicações crônicas da diabetes BR112016027936A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430796A ES2552587B1 (es) 2014-05-28 2014-05-28 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
PCT/ES2015/070415 WO2015181427A1 (es) 2014-05-28 2015-05-27 Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Publications (1)

Publication Number Publication Date
BR112016027936A2 true BR112016027936A2 (pt) 2017-10-24

Family

ID=53546661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027936A BR112016027936A2 (pt) 2014-05-28 2015-05-27 peptídeo derivado de socs1 para o seu uso em complicações crônicas da diabetes

Country Status (13)

Country Link
US (2) US10532082B2 (pt)
EP (1) EP3178485B1 (pt)
JP (1) JP6681387B2 (pt)
CN (1) CN107074922A (pt)
BR (1) BR112016027936A2 (pt)
CA (1) CA2950348A1 (pt)
ES (2) ES2552587B1 (pt)
HU (1) HUE041836T2 (pt)
MX (1) MX369378B (pt)
PL (1) PL3178485T3 (pt)
PT (1) PT3178485T (pt)
TR (1) TR201903509T4 (pt)
WO (1) WO2015181427A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes
CN105315377A (zh) * 2015-12-07 2016-02-10 华东理工大学 带有穿膜肽的tcs融合蛋白、质粒及制备方法与应用
US20200206299A1 (en) * 2016-02-23 2020-07-02 Takeda Pharmaceutical Company Limited Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
CN106349347B (zh) * 2016-10-25 2019-09-13 南通大学 一种小分子多肽、及其编码基因和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175971A1 (en) * 2001-12-28 2003-09-18 Geoffrey Lindeman Differentiation and/or proliferation modulating agents and uses therefor
WO2005086800A2 (en) * 2004-03-04 2005-09-22 Vanderbilt University Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
AU2005330703A1 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
EP1849474B1 (en) 2005-02-15 2016-09-07 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
WO2007010989A1 (ja) 2005-07-20 2007-01-25 Toagosei Co., Ltd. 神経分化誘導ペプチド及びその利用
WO2010151495A2 (en) 2009-06-26 2010-12-29 University Of Florida Research Foundation Inc. Materials and methods for treating and preventing viral infections
US20110229525A1 (en) * 2010-03-12 2011-09-22 Vanderbilt University Modulation of cytokine signaling
WO2013020372A1 (zh) * 2011-08-09 2013-02-14 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CN103173446A (zh) * 2011-12-26 2013-06-26 吕成伟 一种靶向干扰socs1基因的重组腺相关病毒载体的构建方法与应用
ES2552587B1 (es) 2014-05-28 2017-01-18 Fundació Hospital Universitari Vall D'hebron-Institut De Recerca Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes

Also Published As

Publication number Publication date
CA2950348A1 (en) 2015-12-03
US10532082B2 (en) 2020-01-14
ES2552587R1 (es) 2016-02-10
ES2552587A2 (es) 2015-11-30
WO2015181427A1 (es) 2015-12-03
TR201903509T4 (tr) 2019-04-22
JP2017524727A (ja) 2017-08-31
MX369378B (es) 2019-11-07
HUE041836T2 (hu) 2019-05-28
EP3178485B1 (en) 2018-12-12
US20170209536A1 (en) 2017-07-27
PL3178485T3 (pl) 2019-07-31
EP3178485A1 (en) 2017-06-14
ES2552587B1 (es) 2017-01-18
ES2715412T3 (es) 2019-06-04
MX2016015514A (es) 2017-05-04
US20200138903A1 (en) 2020-05-07
CN107074922A (zh) 2017-08-18
PT3178485T (pt) 2019-03-22
JP6681387B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
WO2013166449A3 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
BR112018016001A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
SI2968471T1 (sl) Peptidi za uporabo pri lokalnem zdravljenju nevrodegenerativnih bolezni mrežnice, zlasti v zgodnjih fazah diabetične retinopatije in drugih bolezni mrežnice, pri katerih igra nevrodegeneracija bistveno vlogo
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112016027936A2 (pt) peptídeo derivado de socs1 para o seu uso em complicações crônicas da diabetes
EP3067059A4 (en) Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient
MX2021008663A (es) Anticuerpos mejorados contra il-6.
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
PH12015502263A1 (en) Composition for preventing or treating hangover
BR112016030172A2 (pt) aptâmeros específicos para tlr-4 e usos dos mesmos
UY35747A (es) Derivados sustituidos de fenilalanina
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
UY35745A (es) Derivados sustituidos de fenilalanina
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
BR112016002462A2 (pt) métodos para melhorar os sintomas da asma usando benralizumabe
BR112017024304A2 (pt) processo para a preparação de um extrato de cérebro animal
BR112018072127A2 (pt) inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
WO2013025073A3 (ko) 유홍초 추출물을 함유하는 당뇨합병증 예방 또는 치료용 조성물
BR112018016004A2 (pt) composições e métodos para tratar feridas crônicas
BR112017016333A2 (pt) compostos anticâncer
BR112015029447A2 (pt) novo composto derivados de planta do gênero quamoclit e composição contendo a mesma como ingrediente ativo para a prevenção ou tratamento da diabetes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2724 DE 21/03/2023.